Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura
| Data(s) |
01/01/2015
|
|---|---|
| Formato |
application/pdf |
| Identificador |
http://boris.unibe.ch/78696/1/PubCrawler_01.10.15.tmp.pdf Raval, Jay S.; Padmanabhan, Anand; Kremer Hovinga, Johanna Anna; Kiss, Joseph E. (2015). Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. American journal of hematology, 90(1), E22-E22. Wiley-Liss 10.1002/ajh.23851 <http://dx.doi.org/10.1002/ajh.23851> doi:10.7892/boris.78696 info:doi:10.1002/ajh.23851 info:pmid:25219856 urn:issn:0361-8609 |
| Idioma(s) |
eng |
| Publicador |
Wiley-Liss |
| Relação |
http://boris.unibe.ch/78696/ |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Raval, Jay S.; Padmanabhan, Anand; Kremer Hovinga, Johanna Anna; Kiss, Joseph E. (2015). Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. American journal of hematology, 90(1), E22-E22. Wiley-Liss 10.1002/ajh.23851 <http://dx.doi.org/10.1002/ajh.23851> |
| Palavras-Chave | #610 Medicine & health |
| Tipo |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion PeerReviewed |
